Cargando…
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce serum uric acid levels and have several other potential effects. This multicenter, randomized, open‐label study c...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029836/ https://www.ncbi.nlm.nih.gov/pubmed/33400348 http://dx.doi.org/10.1111/jch.14153 |
_version_ | 1783676058313162752 |
---|---|
author | Kario, Kazuomi Nishizawa, Masafumi Kiuchi, Mari Kiyosue, Arihiro Tomita, Fumishi Ohtani, Hiroshi Abe, Yasuhisa Kuga, Hideyo Miyazaki, Satoshi Kasai, Takatoshi Hongou, Makiko Yasu, Takanori Kuramochi, Jin Fukumoto, Yoshihiro Hoshide, Satoshi Hisatome, Ichiro |
author_facet | Kario, Kazuomi Nishizawa, Masafumi Kiuchi, Mari Kiyosue, Arihiro Tomita, Fumishi Ohtani, Hiroshi Abe, Yasuhisa Kuga, Hideyo Miyazaki, Satoshi Kasai, Takatoshi Hongou, Makiko Yasu, Takanori Kuramochi, Jin Fukumoto, Yoshihiro Hoshide, Satoshi Hisatome, Ichiro |
author_sort | Kario, Kazuomi |
collection | PubMed |
description | Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce serum uric acid levels and have several other potential effects. This multicenter, randomized, open‐label study compared the effects of two XORi, topiroxostat and febuxostat, on arterial stiffness, uric acid levels, and BP in hypertensive patients with hyperuricemia. Patients received topiroxostat 40–160 mg/day or febuxostat 10–60 mg/day, titrated to maintain serum uric acid <6 mg/dl, for 24 weeks. The primary endpoint was change in the cardio‐ankle vascular index (CAVI) from baseline to 24 weeks. There were no significant changes in CAVI from baseline to 24 weeks (from 9.13 to 9.16 [feboxustat] and 8.98 to 9.01 [topiroxostat]). Compared with baseline, there were significant reductions in serum uric acid (–2.9 and –2.5 mg/dl; both p < 0.001) and morning home systolic BP (–3.6 and –5.1 mm Hg; both p < 0.01) after 24 weeks' treatment with febuxostat and topiroxostat. BP decreased to the greatest extent in the subgroup of patients with uncontrolled blood pressure at baseline. Topiroxostat, but not febuxostat, significantly decreased plasma xanthine oxidoreductase activity versus baseline. The urinary albumin‐creatinine ratio (UACR) decreased significantly from baseline to 24 weeks with topiroxostat (–20.8%; p = 0.021), but not febuxostat (–8.8%; p = 0.362). In conclusion, neither topiroxostat nor febuxostat had any significant effects on arterial stiffness over 24 weeks' treatment. |
format | Online Article Text |
id | pubmed-8029836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80298362021-12-16 Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia Kario, Kazuomi Nishizawa, Masafumi Kiuchi, Mari Kiyosue, Arihiro Tomita, Fumishi Ohtani, Hiroshi Abe, Yasuhisa Kuga, Hideyo Miyazaki, Satoshi Kasai, Takatoshi Hongou, Makiko Yasu, Takanori Kuramochi, Jin Fukumoto, Yoshihiro Hoshide, Satoshi Hisatome, Ichiro J Clin Hypertens (Greenwich) Hyperuricemia Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce serum uric acid levels and have several other potential effects. This multicenter, randomized, open‐label study compared the effects of two XORi, topiroxostat and febuxostat, on arterial stiffness, uric acid levels, and BP in hypertensive patients with hyperuricemia. Patients received topiroxostat 40–160 mg/day or febuxostat 10–60 mg/day, titrated to maintain serum uric acid <6 mg/dl, for 24 weeks. The primary endpoint was change in the cardio‐ankle vascular index (CAVI) from baseline to 24 weeks. There were no significant changes in CAVI from baseline to 24 weeks (from 9.13 to 9.16 [feboxustat] and 8.98 to 9.01 [topiroxostat]). Compared with baseline, there were significant reductions in serum uric acid (–2.9 and –2.5 mg/dl; both p < 0.001) and morning home systolic BP (–3.6 and –5.1 mm Hg; both p < 0.01) after 24 weeks' treatment with febuxostat and topiroxostat. BP decreased to the greatest extent in the subgroup of patients with uncontrolled blood pressure at baseline. Topiroxostat, but not febuxostat, significantly decreased plasma xanthine oxidoreductase activity versus baseline. The urinary albumin‐creatinine ratio (UACR) decreased significantly from baseline to 24 weeks with topiroxostat (–20.8%; p = 0.021), but not febuxostat (–8.8%; p = 0.362). In conclusion, neither topiroxostat nor febuxostat had any significant effects on arterial stiffness over 24 weeks' treatment. John Wiley and Sons Inc. 2021-01-05 /pmc/articles/PMC8029836/ /pubmed/33400348 http://dx.doi.org/10.1111/jch.14153 Text en © 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Hyperuricemia Kario, Kazuomi Nishizawa, Masafumi Kiuchi, Mari Kiyosue, Arihiro Tomita, Fumishi Ohtani, Hiroshi Abe, Yasuhisa Kuga, Hideyo Miyazaki, Satoshi Kasai, Takatoshi Hongou, Makiko Yasu, Takanori Kuramochi, Jin Fukumoto, Yoshihiro Hoshide, Satoshi Hisatome, Ichiro Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia |
title | Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia |
title_full | Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia |
title_fullStr | Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia |
title_full_unstemmed | Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia |
title_short | Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia |
title_sort | comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia |
topic | Hyperuricemia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029836/ https://www.ncbi.nlm.nih.gov/pubmed/33400348 http://dx.doi.org/10.1111/jch.14153 |
work_keys_str_mv | AT kariokazuomi comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT nishizawamasafumi comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT kiuchimari comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT kiyosuearihiro comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT tomitafumishi comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT ohtanihiroshi comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT abeyasuhisa comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT kugahideyo comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT miyazakisatoshi comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT kasaitakatoshi comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT hongoumakiko comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT yasutakanori comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT kuramochijin comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT fukumotoyoshihiro comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT hoshidesatoshi comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia AT hisatomeichiro comparativeeffectsoftopiroxostatandfebuxostatonarterialpropertiesinhypertensivepatientswithhyperuricemia |